Selutaront

Selutaront
Clinical data
Drug class	Trace amine-associated receptor 1 (TAAR1) agonist
Identifiers
	IUPAC name 12-methyl-3-thia-9,12-diazatricyclo[7.4.0.02,6]trideca-2(6),4-diene;
PubChem CID	171786782;
Chemical and physical data
Formula	C11H16N2S
Molar mass	208.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCN2CCC3=C(C2C1)SC=C3;
	InChI InChI=1S/C11H16N2S/c1-12-5-6-13-4-2-9-3-7-14-11(9)10(13)8-12/h3,7,10H,2,4-6,8H2,1H3; Key:HIEMMLQFNGZBMB-UHFFFAOYSA-N;

Selutaront is a trace amine-associated receptor 1 (TAAR1) agonist which is being investigated for the potential treatment of schizophrenia.^[1] It is a highly selective, low-potency, high-efficacy partial agonist of the human TAAR1 (EC₅₀Tooltip half-maximal effective concentration = 2,330 nM; E_maxTooltip maximal efficacy = 83%).^[1] The drug shows antipsychotic-like effects in rodents, such as antagonism of dizocilpine (MK-801)-induced hyperlocomotion, without affecting spontaneous locomotor activity when given by itself.^[1] The chemical synthesis of selutaront has been described.^[1] Selutaront was first described in the scientific literature by Jianzhao Zhang and colleagues in 2026.^[1]

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.